DNTH (Dianthus Therapeutics) Current Deferred Revenue: $1.49 Mil (As of Mar. 2026)


DNTH Dianthus Therapeutics Inc DNTH
22 GF Score
Price $98.07
GF Value $2.92
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Current Deferred Revenue?

Dianthus Therapeutics DNTH +2.41% 22 Current Deferred Revenue is $1.49 Mil as of Mar. 2026. GuruFocus rates DNTH with a GF Score™ of 22/100 and a GF Value™ of $2.92 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Dianthus Therapeutics's current deferred revenue for the quarter that ended in Mar. 2026 was $1.49 Mil.

Dianthus Therapeutics Current Deferred Revenue Related Terms

Dianthus Therapeutics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Dianthus Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dianthus Therapeutics Current Deferred Revenue Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
0.00 0.10 0.10 0.48 1.19

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.48 0.95 1.19 1.49
DNTH
22GF Score
Dianthus Therapeutics Inc DNTH
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $1.49 Mil mean?
Dianthus Therapeutics (DNTH) has a Current Deferred Revenue of $1.49 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Dianthus Therapeutics and its competitors.
Is Dianthus Therapeutics' Current Deferred Revenue too high?
Dianthus Therapeutics' current Current Deferred Revenue is $1.49 Mil. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Current Deferred Revenue compare to CAI and TNGX?
Dianthus Therapeutics' Current Deferred Revenue of $1.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Dianthus Therapeutics and its competitors. Dianthus Therapeutics's current Current Deferred Revenue is $1.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (DNTH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.92, compared to a current price of $98.07 — trading 3258.6% above its estimated fair value. The current Current Deferred Revenue is $1.49 Mil. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Dianthus Therapeutics (DNTH), the current Current Deferred Revenue is $1.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dianthus Therapeutics (DNTH) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of $98.07 is trading 3258.6% above its estimated GF Value™ of $2.92. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for DNTH:

  • Current Deferred Revenue: $1.49 Mil
  • GF Value™: $2.92 vs. price of $98.07 (3258.6% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the DNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dianthus Therapeutics Business Description

Other Exchanges 87E:Germany
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for DNTH

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$98.07
Price
$2.92
GF Value